P10-6 Report of a case of sigmoid colon cancer simultaneously harboring the BRAF V600E mutation and NTRK3 fusion gene

Kirio Kawai(Kyorin University), Junji Furuse(Kanagawa Prefectural Hospital Organization), Masato Hayashi(Kanazawa University), Naohiro Okano(Kyorin University), Akira Hirota(Nihon University), Mariko Nishioka(Kyorin University), Tomohiko Taki(Kyorin University), Fumio Nagashima(Kyorin University), Tomonori Mizutani(Kyorin University), Tomohiro Maesono(Social Welfare Organization Saiseikai Imperial Gift Foundation)
Annals of Oncology
July 1, 2022
10.1016/j.annonc.2022.05.246
Cited by 3

Related Papers

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
|The Oncologist|2010|977
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
|British Journal of Cancer|2010|749
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732